2 December 2021, Virtual Conference
Delivered Live (CET) & On Demand Afterwards
Competition Law in the Pharmaceutical Sector
Dissect the competition authorities' newly aggressive approach to the pharma sector including the CMA's new cases, developments in pricing, Article 22 guidance, distribution, follow on damages, patents & much more during this essential 1-day update.
REGULATORS, IN-HOUSE COUNSEL AND TOP LEGAL MINDS FROM ACROSS THE PHARMA INDUSTRY SHARING INSIGHTS:
Your Essential 1-Day Update on Competition Law in the Pharma Sector:
Enforcement Priorities: EU & UK
First hear directly from the Commission on their priorities, then ensure you are up to date with the CMA's recent enforcement including Nortriptyline CAT judgment; Hydrocortisone and Liothyronine CMA decisions; and Phenytoin remittal.
Mergers in the Pharma Sector
During this essential update you'll analyse jurisdiction issues including Article 22 and Illumina-Grail, new theories of harm in merger cases including the new working group established between the US FTC, EC, CMA and Canadian Bureau, killer acquisitions and pipeline products and vertical mergers in the pharma sector.
Distribution & VBER
Gain a practical update on current distribution challenges including a review of the Vertical Block Exemption Regulation and its implication for the pharma sector. Plus, practical strategies when dealing with online sales and parallel trade.
Review horizontal guidelines and their likely impact on the pharma sector and consider practical challenges and strategies to overcome them in cooperation and collaboration agreements.
Pricing in Practice
Join this interactive panel session to discuss practical consequences of recent exclusionary pricing cases and to consider what price increases are permissible in light of them. Then, consider competition law challenges raised by indication-based pricing and pricing of combination therapies.
Discuss recent developments in patents including patent pooling, the Copaxone Investigation and reverse patent settlements - including their implications for patent filing strategies.
Eli Lilly & Co
Of great practical relevance for in-house counsel in the pharmaceutical sector.